Jun Ho Yi

Impact of <i>KRAS</i> Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

Seung Tae Kim, Do Hyoung Lim, Kee‐Taek Jang et al. · Molecular Cancer Therapeutics · 2011 · 141 citations

Kras Mutations, Tumor Biology, First-line Gemcitabine-based Chemotherapy +15

Folate-decorated maleilated pullulan–doxorubicin conjugate for active tumor-targeted drug delivery

Haitao Zhang, Fei Li, Jun Ho Yi et al. · European Journal of Pharmaceutical Sciences · 2011 · 107 citations

Drug Targeting, Nanotherapeutics, Medicine +4

Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer

Su Jin Lee, Silvia Park, Hee Kyung Ahn et al. · Cancer Research and Treatment · 2011 · 98 citations · Full text

Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma

Jun Ho Yi, Gyeong‐Won Lee, Young Rok et al. · Annals of Hematology · 2019 · 74 citations

Lymphoid Neoplasia, Histopathology, Gastroenterology +7

Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma

Jun Ho Yi, Seong Yoon Yi, Hyeran Lee et al. · Melanoma Research · 2011 · 71 citations